Auditory Processing Dysfunction and Tinnitus
Auditory symptoms represent an underrecognized but significant neurological manifestation of ME/CFS, with convergent evidence from functional, epidemiological, systematic, and anatomical studies establishing auditory dysfunction as a documented feature of the disease.
1 Prevalence and Epidemiology
Schubert et al. (Schubert et al. 2021) provided the first large-scale epidemiological evidence linking ME/CFS to tinnitus in a population-based cohort of 124,609 individuals from the Dutch Lifelines study. ME/CFS patients demonstrated 1.57 times higher odds (OR 1.568, p<0.05) of experiencing constant tinnitus compared to healthy controls, identifying ME/CFS as a novel disease associate for tinnitus beyond traditional audiological causes such as noise exposure, age-related hearing loss, and cardiovascular disease.
This finding aligns with earlier cohort studies and patient surveys reporting tinnitus prevalence ranging from 48% to 78% in ME/CFS patients, substantially higher than the 10–15% prevalence in the general population.
Certainty: 0.25. Alzheimer’s disease (AD) exhibits glymphatic clearance failure and BBB compromise paralleling ME/CFS. RVG-HSP70 exosomes could — in principle — simultaneously reduce amyloid burden (via enhanced microglial phagocytosis) and restore sleep architecture in both conditions. The glymphatic-amyloid coupling is well-established in AD; Kang et al.(Kang et al. 2026) demonstrated BDNF/pCREB restoration supporting synaptic plasticity. Whether ME/CFS glymphatic failure produces a metabolite accumulation pattern that would similarly benefit from exosome-enhanced clearance is unknown. This is a cross-disease analogy, not a mechanistic claim about shared pathology.
Certainty: 0.20. Long COVID shares ME/CFS-like symptoms (fatigue, unrefreshing sleep, cognitive dysfunction) and documented exosome abnormalities. If both conditions show exosomal HSP70 deficiency patterns (lower neuron-derived exosomal HSP70 levels correlating with sleep/cognitive severity), this would suggest a shared neuroprotective deficit independent of trigger. No comparative ME/CFS–Long COVID exosome study exists. The Kang et al.(Kang et al. 2026) platform is agnostic to disease aetiology — if the exosomal HSP70 deficiency pattern is shared, the therapeutic concept would apply to both conditions.
Certainty: 0.15. Exosome surface proteins reflect cell of origin and activation state. Mass spectrometry profiling of the exosome surfaceome could identify ME/CFS-specific patterns from under 100 μL plasma — analogous to liquid biopsy approaches in oncology. A 12-protein panel distinguishing ME/CFS from controls with over 75% accuracy would be a clinically useful screening tool but is far from reality. No exosome surfaceome study has been conducted in ME/CFS.
A 2024 systematic review by Skare et al. (Skare et al. 2024) synthesized evidence from 172 articles (1990–2024) documenting ear abnormalities across ME/CFS, fibromyalgia, long-COVID syndrome, postural orthostatic tachycardia syndrome (PoTS), and related conditions. The review identified cochlear complaints—including tinnitus, hearing loss, and hyperacusis—as the most frequent auditory findings in ME/CFS. Four pathophysiological mechanisms were proposed: (1) viral effects on cochlear or central auditory structures, (2) vascular impairment reducing blood flow to the cochlea and brainstem, (3) autoimmune reactions targeting inner ear antigens, and (4) oxidative stress damaging cochlear hair cells and auditory neurons.
The systematic review recommended that all ME/CFS patients with audiological complaints receive ENT consultation and formal audiometry to assess the nature and severity of auditory dysfunction.
2 Functional Auditory Processing Deficits
Beyond subjective tinnitus complaints, objective evidence demonstrates specific auditory processing impairments in ME/CFS patients.
Johnson et al. (Johnson et al. 1996) demonstrated modality-specific cognitive impairment in a controlled comparison of 20 CFS patients, 20 multiple sclerosis (MS) patients, and 20 healthy controls. CFS patients showed differential impairment on auditory versus visual processing tasks, while MS patients showed equal impairment on both modalities. This pattern suggests specific dysfunction in central auditory pathways rather than general cognitive slowing, distinguishing the ME/CFS cognitive profile from the more global impairment observed in other neurological conditions.
Functional MRI studies have further documented that CFS patients recruit additional or atypical brain regions during cognitive and sensory tasks compared to controls Lange et al. (2004), requiring greater neural resources to achieve equivalent task performance. This pattern of compensatory over-recruitment reflects inefficient neural processing consistent with the broader energy-limitation framework.
3 Neuroanatomical Substrate: Brainstem Dysfunction
The functional auditory deficits and elevated tinnitus prevalence in ME/CFS are explained by documented structural and functional abnormalities in brainstem regions critical for auditory processing.
Nelson et al. (Nelson et al. 2021) synthesized MRI evidence from 11 studies demonstrating structural and functional brainstem abnormalities in ME/CFS patients. The brainstem contains the primary central auditory pathway structures:
- Cochlear nucleus (medulla) — receives input from cochlear nerve; first central processing station
- Superior olivary complex (pons) — sound localization via interaural time and intensity differences
- Lateral lemniscus — ascending auditory pathway connecting lower and upper brainstem
- Inferior colliculus (midbrain) — integration of ascending auditory information before thalamic relay
Dysfunction in these structures provides a neuroanatomical substrate explaining both the auditory processing deficits documented by Johnson et al. (Johnson et al. 1996) and the increased tinnitus prevalence observed by Schubert et al. (Schubert et al. 2021).
Importantly, brainstem abnormalities in ME/CFS extend beyond auditory pathways to include autonomic control centers (see Section Autonomic Nervous System Dysfunction), arousal systems (locus coeruleus), and sensory integration regions. This explains the co-occurrence of auditory symptoms with autonomic dysfunction, sleep disturbances, and sensory hypersensitivity—all manifestations of brainstem pathology.
4 Central vs. Peripheral Auditory Pathology
The convergence of functional deficits (Johnson et al. 1996), population-level tinnitus prevalence (Schubert et al. 2021), systematic evidence (Skare et al. 2024), and brainstem MRI abnormalities (Nelson et al. 2021) suggests predominantly central (brainstem) rather than peripheral (cochlear) auditory pathology in ME/CFS. This distinction has important therapeutic implications: neurological approaches targeting brainstem dysfunction, cerebral perfusion, and neuroinflammation may be more effective than peripheral ENT interventions focused solely on the cochlea or middle ear. Evidence supporting central over peripheral pathology includes:
- Auditory processing deficits may occur without peripheral hearing loss on audiometry
- Tinnitus severity often fluctuates with orthostatic stress and cerebral hypoperfusion
- Auditory symptoms co-occur with other brainstem-mediated dysfunction (autonomic, arousal, sensory)
- Hyperacusis (sound sensitivity) suggests central gain dysregulation rather than peripheral damage
- Auditory symptoms are part of broader post-exertional malaise rather than isolated ear pathology
5 Proposed Mechanisms
Based on the systematic review by Skare et al. (Skare et al. 2024) and integration with established ME/CFS pathophysiology, four mechanisms likely contribute to auditory dysfunction (this exemplifies the multi-mechanism pattern characteristic of ME/CFS symptoms, as discussed in Chapter Integrative Models and Multi-System Pathophysiology):
Viral Effects. Direct viral damage to cochlear structures or central auditory pathways may occur during acute infection. This is particularly relevant for post-infectious ME/CFS onset, where viral neurotropism (e.g., EBV, HHV-6) could affect brainstem auditory nuclei. Acute onset of tinnitus following infection supports this mechanism.
Vascular Impairment. Reduced cerebral blood flow documented in ME/CFS (Section Cerebral Blood Flow Abnormalities) likely affects the highly vascularized cochlea and brainstem auditory centers. The stria vascularis in the cochlea maintains the ionic gradient essential for sound transduction and is metabolically active, making it vulnerable to hypoperfusion. Fluctuating tinnitus severity correlating with orthostatic stress supports vascular involvement.
Autoimmune Reactions. Antibodies targeting inner ear antigens (anti-cochlin, anti-HSP70) or auditory brainstem structures may produce autoimmune inner ear disease (AIED). This mechanism aligns with broader autoimmune theories of ME/CFS and suggests potential benefit from immunomodulatory treatment in select patients.
Oxidative Stress. Reactive oxygen species generated by mitochondrial dysfunction and neuroinflammation can damage cochlear hair cells and auditory neurons. The cochlea has high metabolic demands and limited antioxidant capacity, making it vulnerable to oxidative damage. This mechanism connects auditory dysfunction to the mitochondrial pathology documented in ME/CFS.
6 Clinical Implications
6.1 Assessment Recommendations
Based on the documented prevalence and clinical significance of auditory dysfunction:
- Routine screening: All ME/CFS patients should be screened for tinnitus, hearing loss, hyperacusis, and auditory processing difficulties
- Formal audiometry: Patients reporting auditory symptoms should receive comprehensive audiological evaluation
- ENT consultation: Rule out treatable peripheral causes (cerumen impaction, otosclerosis, Ménière’s disease)
- Central auditory testing: Consider auditory brainstem response (ABR) testing to assess central pathways
- Correlation with ME/CFS severity: Document whether auditory symptoms fluctuate with overall disease activity, orthostatic stress, and post-exertional malaise
6.2 Treatment Considerations
Given the proposed central pathology:
- Address underlying ME/CFS pathophysiology: Optimize cerebral perfusion (salt/fluid loading for orthostatic intolerance), treat neuroinflammation, support mitochondrial function
- Symptomatic management: Sound therapy (white noise, tinnitus masking), cognitive-behavioral therapy for tinnitus distress (distinct from CBT as ME/CFS treatment)
- Avoid ototoxic medications: Many drugs can worsen tinnitus (aminoglycosides, loop diuretics, high-dose aspirin, certain chemotherapies)
- Consider immunomodulation: In patients with evidence of autoimmune component (autoantibodies, inflammatory markers)
- Antioxidant support: Alpha-lipoic acid, CoQ10, N-acetylcysteine (extrapolated from evidence in age-related hearing loss and noise-induced damage)
Many ME/CFS patients report that tinnitus intensity increases during post-exertional malaise or correlates with fatigue severity. This pattern suggests tinnitus may function as a real-time indicator of energy depletion or cerebral hypoperfusion. Patients should be educated to recognize worsening tinnitus as a potential warning sign to rest and avoid further exertion.
7 Research Gaps
Despite the convergent evidence for auditory dysfunction in ME/CFS, significant gaps remain:
- Causality: Cross-sectional designs cannot determine whether ME/CFS causes auditory dysfunction, auditory dysfunction contributes to ME/CFS symptoms, or a common mechanism produces both
- Subtype correlation: Unknown whether auditory symptoms predict specific ME/CFS subgroups or correlate with particular biomarkers
- Treatment trials: No randomized controlled trials of auditory-targeted interventions in ME/CFS populations
- Mechanism validation: The four proposed mechanisms (viral, vascular, autoimmune, oxidative) require experimental validation
- Reversibility: Unknown whether treating underlying ME/CFS pathophysiology can reverse auditory dysfunction
- Longitudinal trajectory: Natural history of auditory symptoms in ME/CFS not systematically documented
Hyperacusis (sound sensitivity) in ME/CFS may reflect dysregulated central gain in auditory processing pathways. The brainstem and auditory cortex normally adjust sensitivity (gain) based on environmental demands and context. In ME/CFS, chronic neuroinflammation, altered neurotransmitter levels, or thalamic dysfunction may inappropriately increase central auditory gain, amplifying all sounds and making normal environmental noise intolerable. This would parallel central sensitization in pain pathways. Testing this hypothesis with objective measures of auditory gain (acoustic reflex thresholds, loudness discomfort levels, auditory brainstem response) could clarify mechanisms and guide treatment targeting central gain normalization rather than peripheral protection.
8 Multiple Chemical Sensitivity (MCS) and TRP Sensitization
Multiple chemical sensitivity (MCS) co-occurs with ME/CFS at elevated rates. One mechanistic model proposes that MCS reflects peripheral sensitization of TRPV1 and TRPA1 by prior inflammation or oxidative stress, lowering their activation thresholds below ordinary chemical concentrations (Molot, Sears, and Anisman 2023). TRPA1 is the primary sensor for fragrances, allyl isothiocyanate-containing compounds, and volatile organic chemicals; TRPV1 responds to capsaicin-like molecules and thermal/acid stimuli (Macpherson et al. 2007). In ME/CFS, chronic elevated ROS and prostaglandin production (Section Oxidative and Nitrosative Stress as Symptom Amplifier) could provide the sensitizing milieu. Competing models for MCS include limbic/olfactory kindling, toxicant-induced loss of tolerance (TILT), and central olfactory sensitization; none are mutually exclusive with peripheral TRP sensitization. The TRPV1-mast cell axis (Section Mast Cell Mediators and Histaminergic Symptom Generation) provides an additional mechanism by which chemical stimuli could trigger mast cell degranulation without neuronal firing, contributing to the systemic responses observed in some ME/CFS patients.
9 Proprioceptive Dysfunction and Piezo2 Mechanosensation
Proprioceptive dysfunction — manifesting as impaired sense of body position, unsteady gait, and motor incoordination — has a specific mechanosensory substrate. Piezo2 is the primary mechanotransducer for light touch, vibration, and proprioception in mammals, as established by human loss-of-function mutations producing profound proprioceptive ataxia (Szczot et al. 2018).
Two distinct genetic directions point toward Piezo2 as potentially relevant in ME/CFS, though they predict different phenotypes. Loss-of-function mutations reduce proprioception, potentially explaining motor incoordination in some patients. Gain-of-function Piezo2 variants (Piezo2-CRAMPED syndrome: hypermobility, tactile allodynia, scoliosis) predict heightened mechanosensitivity — features overlapping with hEDS overrepresented in ME/CFS. These are opposite mechanistic directions and cannot both be true simultaneously; which direction, if either, applies in ME/CFS is entirely unknown. Whether any form of Piezo2 dysregulation contributes to ME/CFS symptoms remains unstudied as of 2026.